GW Pharmaceuticals has "high" hopes that its products will help relieve the pain and muscle stiffness that have resulted from multiple sclerosis, cancer, and other ailments. The company develops and sells prescription medicinal drugs derived from cannabis-based medicinal extracts that don't cause a psychotropic high. GW's main product is Sativex, a cannabinoid medicine delivered by an oral spray. Sativex has been approved in Canada, New Zealand, and several European countries for the treatment of muscle stiffness (spasticity) caused by multiple sclerosis. The company is working independently and with partners to expand the drug's uses and markets; it is also working to develop additional cannabinoid therapies.